KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August21, 2017, the compensation committee of the board of directors of KalVista Pharmaceuticals, Inc. (the “Company”) approved an employment agreement with Andreas Maetzel, one of the registrant’s named executive officers, with an annual base salary of $320,000, an annual target bonus equal to 35% of the base salary and a one-time signing bonus of $15,000, which was paid in connection with Mr.Maetzel’s hiring on March8, 2017. to the terms of the employment agreement, if Mr.Maetzel’s employment is terminated either by the Company without “cause” or by the executive for “good reason” (as such terms are defined in the employment agreement), Mr.Maetzel will be entitled to (1)a lump sum payment equal to six months of his base salary and (2)reimbursement for continuation coverage under COBRA for six months. If within two years immediately following the consummation of a “change in control” (as such term is defined in the employment agreement), Mr.Maetzel’s employment is terminated either by the Company without cause or by the executive for good reason, the executive will be entitled to (1)a lump sum cash payment equal to twelve months of his base salary, (2)reimbursement for continuation coverage under COBRA for twelve months and (4)full vesting and exercisability (to the extent applicable) of all outstanding unvested equity-based awards.

The Company’s obligation to provide Mr.Maetzel with any severance payments or other benefits under his employment agreement is conditioned on him signing and not revoking a separation agreement and effective release of claims in the Company’s favor. Mr.Maetzel also entered into an Employee Confidentiality, Invention Assignment and Non-Compete Agreement that prohibits him from competing with the Company and soliciting its employees or other third parties that have a relationship with the Company for one year following his termination of employment for any reason.

Mr.Maetzel also received an option grant to purchase up to 65,000 shares of the Company’s common stock, in connection with his hiring on March8, 2017. Mr.Maetzel is entitled to participate in all employee benefit plans, subject to the general eligibility and participation provisions set forth in such plans. In addition, if Mr.Maetzel relocates to the Boston metropolitan area, he is eligible to be reimbursed for up to $25,000 in relocation expenses.

2

About KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.